Home › Acute Myeloid Leukemia › North Dakota › Bismarck
Acute Myeloid Leukemia clinical trials in Bismarck, ND
3 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Bismarck (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Sanford Bismarck Medical Center, Bismarck
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Sanford Bismarck Medical Center, Bismarck
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Sanford Bismarck Medical Center, Bismarck
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX88 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA41 studies
- Seattle, WA40 studies
- Durham, NC34 studies
- Columbus, OH34 studies
- Philadelphia, PA33 studies
- Atlanta, GA30 studies
- Tampa, FL30 studies
- Chicago, IL27 studies
- Los Angeles, CA25 studies
Other studies in Bismarck
- Lung Cancer9 studies
- Non-Small Cell Lung Cancer6 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Breast Cancer3 studies
- Pancreatic Cancer3 studies
- Kidney Cancer (Renal Cell Carcinoma)3 studies
- Melanoma3 studies
- Prostate Cancer3 studies
- Colorectal Cancer3 studies
- Colon Cancer3 studies
- Hypopharyngeal Cancer3 studies
- Laryngeal Cancer3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.